Erythrocytes from patients with myeloproliferative neoplasms and splanchnic venous thrombosis show greater expression of Lu/ BCAM BCAM

摘要

Abstract Introduction Lutheran/ BCAM protein (Lu) on the surface of erythrocytes is key for their adhesion to the endothelium, and erythrocytes from individuals with JAK 2V617F‐mutated myeloproliferative neoplasms ( MPN ) have increased endothelial adhesion. Splanchnic vein thrombosis ( SVT ) is a devastating thrombotic complication of MPN , and frequently, the only diagnostic feature is the JAK 2V617F mutation. We sought to examine whether erythrocytes from patients with JAK2V617F mutated SVT (MPN‐SVT) exhibited increased Lu expression, thereby supporting a mechanistic contribution to the development of thrombosis. Methods We report the validation of a novel flow cytometry assay for Lu expression on erythrocytes. We examined the expression of Lu on erythrocytes from a cohort of MPN patients with and without SVT , and healthy controls. Samples were obtained from 20 normal individuals, 22 with MPN (both JAK 2V617F‐mutated and wild‐type) and 8 with JAK 2V617F‐mutated MPN‐ SVT . Results Lu expression by erythrocytes from patients with MPN and MPN‐ SVT is significantly increased compared to erythrocytes from healthy individuals ( P ??.05), but there was no significant difference between patients with MPN‐ SVT and MPN . Conclusions Patients with MPN have increased expression of the red cell Lu/ BCAM adhesion molecule. Further work is required to determine the role of the increased Lu/ BCAM adhesion to the endothelium in the development of thrombosis in MPN of all genotypes.